- Report
- August 2025
- 150 Pages
Global
From €3358EUR$3,850USD£2,912GBP
- Report
- October 2025
- 86 Pages
Global
From €4185EUR$4,799USD£3,630GBP
- Report
- March 2025
- 170 Pages
Global
From €4185EUR$4,799USD£3,630GBP
- Report
- September 2025
- 450 Pages
Global
From €4317EUR$4,950USD£3,744GBP
- Report
- February 2026
- 269 Pages
Global
From €5102EUR$5,850USD£4,425GBP
- Report
- June 2025
- 100 Pages
Global
From €5189EUR$5,950USD£4,500GBP
- Report
- June 2025
- 180 Pages
Global
From €5189EUR$5,950USD£4,500GBP
- Report
- January 2026
- 191 Pages
Global
From €3435EUR$3,939USD£2,979GBP
- Report
- January 2026
- 183 Pages
Global
From €3435EUR$3,939USD£2,979GBP
- Report
- January 2026
- 190 Pages
Global
From €3435EUR$3,939USD£2,979GBP
- Report
- January 2026
- 185 Pages
Global
From €3435EUR$3,939USD£2,979GBP
- Report
- January 2026
- 196 Pages
Global
From €3435EUR$3,939USD£2,979GBP
- Report
- January 2026
- 185 Pages
Global
From €3435EUR$3,939USD£2,979GBP
- Report
- January 2026
- 187 Pages
Global
From €3435EUR$3,939USD£2,979GBP
- Report
- January 2026
- 182 Pages
Global
From €3435EUR$3,939USD£2,979GBP
- Report
- August 2025
- 188 Pages
Global
From €3435EUR$3,939USD£2,979GBP
- Report
- August 2025
- 190 Pages
Global
From €3435EUR$3,939USD£2,979GBP
- Report
- August 2025
- 181 Pages
Global
From €3435EUR$3,939USD£2,979GBP
- Report
- August 2025
- 192 Pages
Global
From €3435EUR$3,939USD£2,979GBP
- Report
- August 2025
- 187 Pages
Global
From €3435EUR$3,939USD£2,979GBP

The RNA Vaccine market is a subset of the larger Vaccine market, which is composed of products designed to prevent and treat infectious diseases. RNA Vaccines are a relatively new type of vaccine, which use genetic material to stimulate an immune response. This type of vaccine is particularly attractive due to its potential to be quickly developed and manufactured, as well as its ability to target a wide range of diseases.
RNA Vaccines are being developed for a variety of diseases, including influenza, malaria, and cancer. These vaccines are being studied in clinical trials, and some have already been approved for use in humans.
The RNA Vaccine market is expected to grow in the coming years, as more vaccines are developed and approved. This growth is driven by the increasing demand for vaccines, as well as the potential for RNA Vaccines to be used to treat a wide range of diseases.
Some companies in the RNA Vaccine market include Moderna, Inovio Pharmaceuticals, CureVac, and Arcturus Therapeutics. Show Less Read more